Sef P. Kurstjens
Director/Board Member chez UROVANT SCIENCES LTD.
Profil
Sef P.
Kurstjens is currently working as a Director at Roivant Sciences, Inc. He is also an Independent Director at Urovant Sciences Ltd.
and holds the position of Chief Medical Officer & Executive Vice President at Urovant Sciences, Inc. In his former positions, Dr. Kurstjens served as the President & Chief Executive Officer at Agensys, Inc. from 2010 to 2013.
He was also the Vice President-Worldwide Therapeutic at Pfizer Inc. from 1993 to 2005.
Additionally, he held the role of Chief Medical Officer at Astellas Pharma, Inc. from 2013 to 2018 and Chief Medical Officer at Allergan Ltd.
(Ireland) from 2007 to 2010.
He also served as the Chief Medical Officer at Astellas Pharma Global Development, Inc. from 2013 to 2018.
Dr. Kurstjens completed his undergraduate degree from the University of the Witwatersrand in 1990.
Postes actifs de Sef P. Kurstjens
| Sociétés | Poste | Début |
|---|---|---|
| UROVANT SCIENCES LTD. | Director/Board Member | 01/07/2018 |
Urovant Sciences, Inc.
 Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The private company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | Chief Tech/Sci/R&D Officer | 04/04/2022 |
Roivant Sciences, Inc.
 Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Director/Board Member | - |
Anciens postes connus de Sef P. Kurstjens
| Sociétés | Poste | Fin |
|---|---|---|
| ASTELLAS PHARMA INC. | President | 01/04/2018 |
Astellas Pharma Global Development, Inc.
 Astellas Pharma Global Development, Inc. Pharmaceuticals: MajorHealth Technology Astellas Pharma Global Development, Inc. provides business services. The company is headquartered in Deerfield, IL. | Chief Tech/Sci/R&D Officer | 01/04/2018 |
Agensys, Inc.
 Agensys, Inc. Miscellaneous Commercial ServicesCommercial Services Agensys, Inc. develops a pipeline of therapeutic fully human monoclonal atibodies (mAbs) to treat cancer. It develops a pipeline of naked and antibody-drug conjugated (ADC) therapeutic antibodies to treat cancer indications, including prostate, kidney, pancreas, ovary, bladder, lung, colon, breast, and skin. The company was founded in 1997 and is headquartered in Santa Monica, CA. | Chief Executive Officer | 01/01/2013 |
| ALLERGAN PLC | Chief Tech/Sci/R&D Officer | 01/01/2010 |
| PFIZER, INC. | Corporate Officer/Principal | 01/01/2005 |
Formation de Sef P. Kurstjens
| University of the Witwatersrand | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| ASTELLAS PHARMA INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Agensys, Inc.
Agensys, Inc. Miscellaneous Commercial ServicesCommercial Services Agensys, Inc. develops a pipeline of therapeutic fully human monoclonal atibodies (mAbs) to treat cancer. It develops a pipeline of naked and antibody-drug conjugated (ADC) therapeutic antibodies to treat cancer indications, including prostate, kidney, pancreas, ovary, bladder, lung, colon, breast, and skin. The company was founded in 1997 and is headquartered in Santa Monica, CA. | Commercial Services |
| California Healthcare Institute | Health Technology |
Allergan Ltd. (Ireland)
 Allergan Ltd. (Ireland) Pharmaceuticals: MajorHealth Technology Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1982 and is headquartered in Dublin, Ireland. | Health Technology |
Astellas Pharma Global Development, Inc.
Astellas Pharma Global Development, Inc. Pharmaceuticals: MajorHealth Technology Astellas Pharma Global Development, Inc. provides business services. The company is headquartered in Deerfield, IL. | Health Technology |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Health Technology |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The private company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | Health Technology |
Urovant Sciences Ltd.
 Urovant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which through its subsidiaries, engages in the development and commercialization of therapies for urologic conditions. Its pipeline includes Vibegron (RVT-901) and URO-902. The company was founded on January 27, 2016 and is headquartered in London, the United Kingdom. | Health Technology |
